#USA #Los Angeles #Schall Law Firm #Securities Fraud #ADMA Biologics

ADMA Biologics Investor Alert: Join the Class Action

The Schall Law Firm, a prominent name in shareholder rights litigation, has taken the initiative to alert investors about a class action lawsuit concerning ADMA Biologics, Inc. This lawsuit claims that the company may have violated key provisions of the Securities Exchange Act of 1934, specifically Sections 10(b) and 20(a) and Rule 10b-5 as mandated by the U.S. Securities and Exchange Commission.

What is the Class Action About?

The lawsuit targets ADMA Biologics, a biotechnology firm specializing in developing treatments derived from human plasma. Investors who purchased ADMA securities during the specified period from August 9, 2024 to March 25, 2026, are encouraged to reach out to the Schall Law Firm. If your investments suffered losses within this timeframe, it may be crucial for you to consider participating in this legal action.

The litigation centers around allegations that ADMA made misleading statements regarding its financial health and operational practices. According to the complaint, the firm engaged in undisclosed related party transactions and employed questionable methods such as channel stuffing to artificially inflate its revenue figures. These actions, if proven true, indicate a severe lapse in corporate governance and transparency, potentially disadvantaging investors who trusted the company's public disclosures.

Legal Representation and Support

Brian Schall, a leading attorney at the Schall Law Firm, offers a free consultation for shareholders affected by this situation. Interested parties can reach out directly to discuss their rights and how to reclaim their losses. Specifically, the firm’s contact information is readily available for those seeking help:

• - Address: 2049 Century Park East, Suite 2460, Los Angeles, CA 90067
• - Phone: 310-301-3335
• - Website: www.schallfirm.com

It’s important to note that the class involved in this case has not yet been certified. This means that potential participants remain unrepresented unless they take action by joining the lawsuit.

The Importance of Taking Action

Investors should be aware of their rights, especially in cases involving potential securities fraud. By coming together in a class action, investors can pool resources and strengthen their position against larger corporate entities. Historically, class action lawsuits provide a vital avenue for investors to seek justice and recover from financial losses due to corporate dishonesty.

In this increasingly complex market, maintaining transparency in corporate actions is paramount to investor trust. When companies engage in actions detrimental to shareholders, it not only impacts the stock price but erodes the very foundation of investor confidence.

Now is the time for ADMA Biologics investors to evaluate their options. While the lawsuit is still in its early stages, early participation might be key to maximizing recovery chances. The potential implications of this lawsuit are significant, not just for ADMA Biologics, but for investor rights as a whole.

Conclusion

The Schall Law Firm stands ready to assist investors impacted by the alleged misdeeds of ADMA Biologics, Inc. As someone who invested during the affected period, now is the moment to scrutinize your options and determine if participation in this class action is right for you. Taking action can provide a route to recover losses and send a strong message about corporate accountability. Don’t hesitate to seek the information and guidance necessary to make an informed decision about your investment rights.